CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 24 enrolled
Drug / intervention
Sono-guided injection with ES135 +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06328166
NCT06328166N/ACompleted

The Effect and Safety of Recombinant Human Fibroblast Growth Factor-1 for Patient With Carpal Tunnel Syndrome

Tri-Service General Hospital·interventional·Posted Mar 25, 2024·Updated Sep 10, 2025

In Brief

A clinical study evaluating Sono-guided injection with ES135 and Sono-guided injection with placebo for Carpal Tunnel Syndrome. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Carpal tunnel syndrome (CTS) is a common peripheral entrapment mononeuropathy of the upper limb, which results from compression of median nerve at level of wrist. In recent years, regenerative medicine has gradually been applied in the treatment of various degenerative conditions such as bones, muscles, and nerves. Human fibroblast growth factor 1 is a single-chain protein , which has been shown to play a crucial regulatory role in the brain and spinal cord and can facilitate nerve cell differentiation and growth. ES135 is a recombinant human fibroblast growth factor 1 (rhFGF1) which is composed of 135 amino acids with a molecular weight of approximately 15.2 kilodalton. Several studies have shown that significant improvement of Functional Independence Measure, motor and sensory function of spinal cord injury patients after ES135 treatment. One study also revealed the muscle strength have significant improvement in brachial plexus injury patients after ES135 therapy. According to above studies, the investigators hypothesized that ES135 may have benefits to CTS patients. Hence, the purpose of this study aim to demonstrate the therapeutic effects and safety of ES135 for CTS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTaiwan

Timeline

N/ACompletedFinished
20252026
First PostedMar 25, 2024
Enrollment StartMar 22, 2024
Primary CompletionMay 30, 2025
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 2.3 years ago

Interventions

Sono-guided injection with ES135procedure

Sono-guided injection with ES135 between carpal tunnel and median nerve

Sono-guided injection with placeboprocedure

Sono-guided injection with placebo between carpal tunnel and median nerve